Compare NEXT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEXT | MESO |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 81 |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2014 | N/A |
| Metric | NEXT | MESO |
|---|---|---|
| Price | $7.66 | $18.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 220.4K |
| Earning Date | 05-01-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $629.74 |
| Revenue Next Year | N/A | $30.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.75 | $11.87 |
| 52 Week High | $12.12 | $21.50 |
| Indicator | NEXT | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 75.11 |
| Support Level | $6.93 | $17.90 |
| Resistance Level | $8.83 | $18.89 |
| Average True Range (ATR) | 0.36 | 0.47 |
| MACD | 0.06 | 0.40 |
| Stochastic Oscillator | 46.61 | 97.35 |
NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas, the sale of LNG, and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions, advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.